Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway AberrationsDigestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasmRecruitingPhase 12026-09-23NCT06915753

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Tyra Biosciences, Inc7

16 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Asan Medical CenterSeoulSouth Korea131
Columbia University Irving Medical CenterNew YorkUnited States1
John Hopkins UniversityBaltimoreUnited States4
Karmanos Cancer InstituteDetroitUnited States153
Mass General Cancer CenterBostonUnited States5
National Taiwan University HospitalTaipeiTaiwan203
Samsung Medical CenterSeoulSouth Korea170
Sarah Cannon Research Institute Oncology PartnersNashvilleUnited States12
Seoul National University HospitalSeoulSouth Korea183
Severance Hospital, Yonsei University Health SystemSeoulSouth Korea43
Stanford Cancer InstituteStanfordUnited States19
Taipei Veterans General HospitalTaipeiTaiwan64
The University of Kansas Medical CenterWestwoodUnited States3
UCSF Medical Center at Mount ZionSan FranciscoUnited States1
University Health Network Princess Margaret Cancer CenterTorontoCanada1
Usc Norris Comprehensive Cancer CenterLos AngelesUnited States67